Literature DB >> 32642998

ASO Author Reflections: The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis.

Yoshikuni Kawaguchi1,2, Jean-Nicolas Vauthey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32642998     DOI： 10.1245/s10434-020-08809-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  3 in total

1.  Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Clin Cancer Res       Date:  2019-06-20       Impact factor: 12.531

2.  Fast-Track Two-Stage Hepatectomy Using a Hybrid Interventional Radiology/Operating Suite as Alternative Option to Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy Procedure.

Authors:  Bruno C Odisio; Eve Simoneau; Alex A Holmes; Claudius H Conrad; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2018-05-04       Impact factor: 6.113

3.  Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.

Authors:  John A Bridgewater; Siân A Pugh; Tom Maishman; Zina Eminton; Jane Mellor; Amy Whitehead; Louise Stanton; Michael Radford; Andrea Corkhill; Gareth O Griffiths; Stephen Falk; Juan W Valle; Derek O'Reilly; Ajith K Siriwardena; Joanne Hornbuckle; Myrddin Rees; Timothy J Iveson; Tamas Hickish; O James Garden; David Cunningham; Timothy S Maughan; John N Primrose
Journal:  Lancet Oncol       Date:  2020-01-31       Impact factor: 41.316
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.